Physician profile
Andy Langston
NPI 1336112465
$614.35
in general payments reported to CMS, 2019-2025
15 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.48 · 2021: $109 · 2022: $127 · 2023: $89.51 · 2024: $154 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $136.11 | 2019-2024 | Idose, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Johnson & Johnson Vision Care, INC. | $130.50 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $103.54 | 2022-2025 | Infuse |
| Biotissue Holdings INC. | $34.60 | 2021-2022 | |
| Abbvie INC. | $28.20 | 2023 | |
| Kala Pharmaceuticals, INC. | $24.48 | 2021 | |
| Oyster Point Pharma, INC. | $23.38 | 2022 | |
| Rxsight INC | $21.09 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $20.47 | 2021 | |
| Optos, INC. | $20.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.85 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.02 | 2022 | |
| Alcon Vision LLC | $14.68 | 2025 | Precision7 |
| Abb Con-Cise Optical Group LLC | $12.53 | 2021 | |
| Coopervision INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Langston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.